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1) SIGNIFICANCE
 When designing disease treatments, there are several
disadvantages of introducing free drug to a patient:
• Burst Kinetics, toxic off site effects, and low efficacy due
to systematic dilution
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 Drug delivery attempts to solve these problems by
controlling the spatial (location) and temporal (timing)
characteristics of drug release!
 Substrate mediated delivery, the release of drug from a
surface or object, offers a unique way in which to control
these characteristics.
• Substrate mediated delivery of cargo has shown great
promise in applications including drug and gene
eluding films/scaffolds [1,2], coatings for stents [3] and
other implantable devices [4]
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2) POLYELECTROLYTE MULTILAYERS
(PEMs) AND LIPOSOMES NANOPARTICLES
 PEMs are thin polymer
films which are constructed of
(LNPs)
layers of oppositely charged polyelectrolytes.
• Simple to assemble on biomedical surfaces
• Have been used to entrap small molecule drugs [5],
proteins [6], and nucleic acids [7,8]

 Liposomes nanoparticles are the most researched,
tested, and commercialized drug delivery carrier.
• Can entrap hydrophilic and hydrophobic cargo
• Easy to functionalize and excellent biocompatibility

 PEM entrapped liposomes have been explored, but
maintaining the stability of the liposomes in the PEM
structure has been the primary advancement to this point.

3) PROJECT OBJECTIVE
In this project, we report the engineering of a novel liposome
(HALNP) embedded PEM substrate (HALNP-PEM) for the
local and sustained delivery of therapeutic cargo.

Fig. 2. Hyaluronic Acid (HA) decorated lipid nanocarrier fabrication overview and characterization.
Fluorescent Microscopy and release studies demonstrate ionically driven HALNP entrapment, and
minimized HALNP release by addition of capping polymer layers. (A) Lipid nanoparticles (LNPs) were
surface functionalized with HA (HALNPs) via EDC facilitated amide bond formations. (B) Transition Electron
Microscopy (TEM) images of particles pre- and post- HA addition. (C) Preferential deposition of HALNPs on
PLL over SPS topped surfaces. Capillary Force Lithography (CFL) was used to create PLL patterns on
(PLL/SPS)4 and to demonstrate the level of spatial control for nanoparticle adsorption. (D) Fluorescent
Recovery after Photobleaching (FRAP) Analysis pre and post the addition of the capping layer for 10 minutes
(yellow arrows point out particles that have moved). (E) HALNP nanocarrier release profile from the noncapped [(PLL/SPS)4.5(HALNP)] and capped [(PLL/SPS)4.5(HALNP)(PLL/SPS)2.5] HALNP-PEM platforms.

5) FLUORESCENTLY TAGGED HALNPs ARE TAKEN UP FROM
SUBSTRATE BY 21MT-1 CELLS
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• Entrapment is verified and release kinetics are analyzed.
• A cell driven mechanism of release for HALNPs is
hypothesized.
• Doxorubicin (DOX) is delivered to 21M-T metastatic breast
cancer in vitro.
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Fig. 1. Project Objective Overview

Fig. 3. 21MT-1 localized uptake of
fluorescently labeled particles. (A)
Flow Cytometry Analysis of percent
cell population FITC positive and per
cell fluorescence directly comparing
nanoparticle uptake between the
HALNP-PEM and HALNP bolus
systems (*P < 0.05, **P < 0.005; n =
3; #denotes significance between a
specific sample type and the
preceding time point following the
same significance scale as the stars).
(B) Phase Contrast and Fluorescent
Microscopy visual investigation of
nanoparticle intracellular delivery on
the HALNP-PEM platform. CFL was
used to pattern HALNPs beneath the
capping layers. Note that only the
cells attached directly above the
particles become fluorescent.

Fig. 4. DOX Toxicity Assay and 21MT-1 localized uptake of DOX
Therapeutic. (A) Doxorubicin potency assay comparison between Free
Dox, DOX encapsulated in HALNPs (HALNPDOX) in the bolus form,
and HALNPDOX nanoparticles embedded into the PEM platform
(HALNPDOX-PEM). Standard MTT protocol was used to determine the
percent viable cells at 24 hours. (B) Localized delivery of DOX
therapeutic. Note that cells attached directly above DOX loaded
HALNPs become predominantly fluorescent.

7) CONCLUSIONS
 HALNP-PEM system entraps and stabilizes drug loaded
liposomes through ionic interactions.
 The locally driven uptake of fluorescent and drug loaded
nanoparticles supports the hypothesis of a cell mediated
degradation mechanism of the PEM substrate.
 HALNPs are taken up by attached cells, and drug loaded
substrate embedded particles show competitive efficacy.
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